ASP Isotopes (ASPI) investor relations material

Strategic vision and growth plans

• Transitioning from a development-focused company to scaling operations globally, aiming to become a leading supplier of critical materials, including isotopes, helium, and nuclear fuels over the next five years.

• Focus on four operating divisions: Nuclear Medicine, Electronics, Noble Africa (helium/LNG), and Nuclear Fuels, all built since 2021.

• Targeting $300–$700 million in EBITDA by 2031, driven by expansion in radiopharmaceuticals, isotope enrichment, helium/LNG, and nuclear fuel businesses.

• Plans include global expansion of PET Labs, construction of additional isotope enrichment plants, and completion of phase II of the Virginia Gas Project.

• Intends to spin out Quantum Leap Energy and list Noble Africa, focusing on maximizing shareholder value through asset separation and targeted growth.

Financial outlook and capital allocation

• Ended Q2 with $255 million in cash, reflecting strong historical fundraising and investment in infrastructure.

• Anticipates a $40–$60 million annual burn rate over the next 24 months, with expectations to reach positive operating cash flow as new businesses generate revenue.

• 2Q 2026 revenue of $5.1M; FY2026 forecast of $14M, primarily from radiopharmaceuticals.

• Major revenue drivers for 2031 include helium/LNG sales, isotope shipments, radiopharmacy expansion, and new plant deployments.

• Gross margins expected to exceed 80% for helium/LNG, 70%+ for radiopharmacies, and 50–80% for various isotopes.

Business developments and operational highlights

• Achieved operational status for multiple isotope and cryogenics plants, with commercial production of helium and isotopes commencing in 2023.

• PET Labs delivering over 10,000 doses and forecasted to generate $14M revenue in 2026.

• Noble Africa’s Virginia Gas Project Phase 1 ahead of schedule, targeting 70 mcf/day helium and 2,500 GJ/day LNG, with first production expected before September 30, 2026.

• Alpha Theranostics advancing VHH antibody-based theranostics for hard-to-treat cancers, targeting first human data within 12 months.

• Quantum Leap Energy progressing on domestic and international uranium and lithium enrichment, with partnerships for HALEU supply and new conversion facilities in the U.S. and Namibia.